Renalytix Unveils Enhanced Risk Assessment Data for Kidney Disease

The latest update is out from Renalytix ( (GB:RENX) ).

Renalytix announced new data from its kidneyintelX.dkd test at the European Renal Association Congress 2025, demonstrating enhanced risk assessment capabilities in diabetic kidney disease. The data showed that the test could reclassify patient risk levels more accurately than standard measures, leading to more efficient treatment allocation and improved patient outcomes, particularly when combined with SGLT2 inhibitors. This advancement supports the implementation of guideline-directed care and highlights the potential for kidneyintelX.dkd to reduce healthcare costs and patient suffering.

Spark’s Take on GB:RENX Stock

According to Spark, TipRanks’ AI Analyst, GB:RENX is a Underperform.

Renalytix’s overall stock score is low due to severe financial challenges, including declining revenues, high operating losses, and solvency issues. Despite positive corporate events suggesting strategic interest and growth potential, the technical analysis and valuation remain weak, impacting the stock’s appeal.

To see Spark’s full report on GB:RENX stock, click here.

More about Renalytix

Renalytix is an artificial intelligence-enabled in vitro diagnostics company focused on optimizing clinical management of kidney disease to improve patient outcomes. The company has developed kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test for early-stage risk assessment in chronic kidney disease, which is now being deployed across the United States.

Average Trading Volume: 133,802

Technical Sentiment Signal: Sell

Current Market Cap: £24.01M

For detailed information about RENX stock, go to TipRanks’ Stock Analysis page.